Related Experiment Video

Updated: Aug 12, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Drug-targeting strategies in cancer therapy

P S Huang1, A Oliff

  • 1Dupont Pharmaceuticals Co., Department of Cancer Research, Glenolden, Pennsylvania 19036, USA.

Current Opinion in Genetics & Development
|February 13, 2001
PubMed

Insights

Genetic alterations drive cancer by affecting cell cycle and survival pathways. Researchers propose targeting tumor-specific enzymes to activate chemotherapy, enhancing cancer treatment efficacy and reducing side effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Tumorigenesis arises from genetic alterations in cell-cycle, apoptotic, and survival pathways.
  • Transformed cells exhibit distinct phenotypic changes within the tumor microenvironment.
  • Key tumor-associated changes include elevated surface proteases, increased angiogenesis, and heightened glucuronidase activity.

Purpose of the Study:

  • To explore strategies for improving the therapeutic index of existing cancer therapies.
  • To investigate the potential of exploiting tumor-specific enzymatic activity for targeted drug delivery.
  • To evaluate enzymatic activation of cytotoxics as a method to enhance chemotherapeutics.

Main Methods:

  • Analysis of genetic changes leading to tumorigenesis.
  • Characterization of phenotypic changes in transformed cells.
  • Assessment of tumor microenvironment characteristics such as protease, angiogenesis, and glucuronidase activity.

Main Results:

  • Genetic modifications in critical cellular pathways initiate cancer development.
  • Tumor cells display unique environmental markers, including increased enzymatic activity.
  • These tumor-specific markers present opportunities for targeted therapeutic interventions.

Conclusions:

  • Exploiting the unique enzymatic profile of the tumor microenvironment offers a promising approach for cancer therapy.
  • Enzymatic activation of cytotoxic agents can improve drug targeting and efficacy.
  • This strategy holds potential for enhancing the therapeutic index of chemotherapeutics.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Screening Ion Channels in Cancer Cells06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.